YazanMadanatMD

Hematology/Oncology

Assistant Professor of Medicine Director of MDS Clinic UTSW Simmons Comprehensive Cancer Center

Dr. Madanat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-2661

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2016 - 2019
Cleveland Clinic FoundationResidency, Internal Medicine, 2013 - 2016
University of Jordan Faculty of MedicineClass of 2011

PubMed

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropo...
Mikkael A Sekeres, Valeria Santini, Maria Díez-Campelo, Rami S Komrokji, Pierre Fenaux
Leukemia & Lymphoma. 2025-03-01
1 citations
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.
Tamanna Haque, Aditi Shastri, Pinkal Desai, Zhuoer Xie, Danielle Hammond
British Journal of Haematology. 2025-02-01
Clinicopathologic and Molecular Characterization of NUP98-Rearranged Acute Leukemias.
Sujata Sajjan, Estelle E Oertling, Franklin Fuda, Jeffrey Gagan, Prasad Koduru
International Journal of Laboratory Hematology. 2025-01-21

Abstracts/Posters

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
Yazan F. Madanat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsMarch 18th, 2019
ASH 2018: Dec 1-4December 1st, 2017